Please review our visitor restrictions before coming to our hospitals or clinics. | Get the latest on COVID-19.

There is no panel matching the key "MicroAlert"

Cancer & Blood Disorders Clinical Trials

Gundersen Health System has about 100 research studies available for cancer patients at any given time.

NCORP badge

With support from Gundersen Medical Foundation, the Cancer and Blood Disorders Center offers research studies through participation in regional and national cancer treatment cooperative groups. By sharing clinical research efforts and measuring collective results, treatments are advanced more rapidly than any institution can accomplish alone. Participation in these groups can shorten the time it takes for us to get new, more effective drugs on the market.

Sometimes patients are concerned that if they don't get the experimental therapy, they will only get a placebo. However, in cancer research, the patient will either get the standard treatment or the new experimental drug that has shown signs to be potentially better than the standard treatment. Not everyone will qualify for a cancer research study, but for those who do, it can offer new hope.

Brain/Central Nervous System Cancer

  • Alliance A071702: A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma

  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • Alliance N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
  • COG ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
    • *AGE: ≥ 3 years and < 22 years of age at the time of enrollment
  • COG ACNS1721: A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600 Mutations
    • *AGE: Stratum 2 (IDH mutant): ≥ 3 years of age and ≤ 25 years of age at the time of enrollment.
  • Wake Forest WF 1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Breast Cancer

EARLY STAGE

Neoadjuvant

Inflammatory

  • SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer.
  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

Post-Neoadjuvant

  • Alliance A011202: A randomized phase III Trial Comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy.
  • Alliance A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

Adjuvant

  • CCTG.MA.39 TailorRT (RT): Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (TAILOR RT)
  • NRG-BR003 (TNBC): A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

ADVANCED/METASTATIC

  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Gastrointestinal Cancer

COLON

Adjuvant

  • A021502: Randomized Trial of Standard Chemotherapy
    Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Metastatic

  • NRG-GI004: Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
  • SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification (Suspended 5/16/2019)
  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • SWOG S1609:"DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

RECTAL

Adjuvant

  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Metastatic/Advanced

  • NRG-GI004: Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
  • SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification (Suspended 5/16/2019)
  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • SWOG S1609:"DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

ANAL

  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

CHOLANGIOCARCINOMA

  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

PANCREATIC

  • Alliance A021806: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
  • ECOG EA2186: A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

GASTRIC

  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

ESOPHAGEAL

  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

HEPATIC

  • COG AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
    • *AGE: ≤ 30 years of age at the time of diagnosis
  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Genitourinary Cancer

BLADDER

Adjuvant

  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

Neoadjuvant

  • Alliance A031701: A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

Metastatic/Advanced

  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • ECOG EAY131 MATCH:Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

PROSTATE

  • NRG-GU005: Phase II IGRT And SRBT Vs IGRT And Hypofractionated IMRT For Localised Intermediate Risk Prostate Cancer
  • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
  • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
  • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

RENAL

    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
    • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
    • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    Germ Cell Tumors

    • COG AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
      • *AGE: Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites)) Patients must be < 50 years of age at enrollment.
      • Standard Risk 1 Patients must be < 11 years of age at enrollment.
      • Standard Risk 2 Patients must be ≥ 11 and < 25 years of age at enrollment.
    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
    • ECOG EAY131 MATCH:Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    Gynecological Cancer

    CERVICAL

    • GOG 0263: Phase III Randomized Study of Adjuvant Radiation Versus Chemoradiation Therapy in Patients With Intermediate-Risk Stage I-IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
    • RTOG 0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiotherapy With Versus Without Adjuvant Chemotherapy in Patients With High-Risk Early-Stage Cervical Carcinoma After Radical Hysterectomy
    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
    • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
    • ECOG EAY131 MATCH:Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    ENDOMETRIAL

    • NRG-GY020: A Phase III Randomized Trial of Radiation +/- M-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometriod Endomtrial Cancer
    • Lunchbox: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel for Optimally Debulked Advanced Endometrial Carcinoma
    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
    • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
    • ECOG EAY131 MATCH:Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE

    • NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
    • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
    • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    Head and Neck Cancer

    • ECOG-ACRIN EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
    • NRG-HN001: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
    • NRG-HN005: A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
    • RTOG 1216 - Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
    • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
    • ECOG EAY131 MATCH:Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas.

    Immuno-Oncology

    • A151804: Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

    Leukemia

    ACUTE LEUKEMIA

    ALL

    • COG AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome (DS) B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
      • *AGE: ≥ 365 days and < 10 years of age (B-ALL patients without DS)
      • ≥ 365 days and ≤ 31 years of age (B-ALL patients with DS)
      • ≥ 365 days and ≤ 31 years of age (B-LLy patients with or without DS)
    • COG AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#:772518) for Newly Diagnosed High‐Risk B‐ALL; Risk Adapted Post‐Induction Therapy for High‐Risk B‐ALL, Mixed Phenotype Acute Leukemia, and Disseminated B‐LLy
      • *AGE: > 365 days and < 25 years of age at diagnosis

    • COG AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
      • *AGE: > 1 year and < 21 years at ALL diagnosis
    • The Gundersen Lutheran Bio-Bank Project I: Collection of Biological Specimens for Medical Research from Patients with Blood and Marrow Disorders
    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

    AML

    • The Gundersen Lutheran Bio-Bank Project I: Collection of Biological Specimens for Medical Research from Patients with Blood and Marrow Disorders
    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

    APL

    • The Gundersen Lutheran Bio-Bank Project I: Collection of Biological Specimens for Medical Research from Patients with Blood and Marrow Disorders
    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

    MPAL

    COG AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#:772518) for Newly Diagnosed High‐Risk B‐ALL; Risk Adapted Post‐Induction Therapy for High‐Risk B‐ALL, Mixed Phenotype Acute Leukemia, and Disseminated B‐LLy

    • *AGE: > 365 days and < 25 years of age at diagnosis

    CHRONIC LEUKEMIA

    • A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
    • The Gundersen Lutheran Bio-Bank Project I: Collection of Biological Specimens for Medical Research from Patients with Blood and Marrow Disorders
    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

    Lung Cancer

    NSCLC (Non-Small Cell Lung Cancer)

    • SWOG S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

    • Alliance A171901: Older Non-Small Cell Lung Cancer Patients (>/= 70YEARS OF AGE) Treated with First line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist's/Patient's Choice)

    • Alliance A151216: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (ALCHEMIST Treatment Trial)
      • Sub Studies for A151216:
        • Alliance A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
        • ECOG E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
    • ECOG EA5191: A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
    • ECOG EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
    • NRG-LU002: Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
    • SWOG LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
      • Sub Studies for LUNGMAP:
        • S1900E - A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

    • ECOG EA5181 - Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

    • ECOG EA5182 - Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
    • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
    • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    SMALL CELL LUNG CANCER

    • S1827 - MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

    • SWOG S1929 - Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    • NRG-CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
    • NRG – LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
    • NRG-LU007: Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

    • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
    • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    MESOTHELIOMA

    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
    • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
    • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    Lymphoma

    HODGKIN'S

    • SWOG S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.
    • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    NON-HODGKIN'S

    Diffuse Large B-Cell Lymphoma

    • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    Follicular Lymphoma

    • SWOG S1608: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma- Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in treating patients with relapsed or refractory grad I-IIIa Follicular Lymphoma
    • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    Lymphoblastic Lymphoma

    • COG AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome (DS) B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
      • *AGE: ≥ 365 days and < 10 years of age (B-ALL patients without DS)
      • ≥ 365 days and ≤ 31 years of age (B-ALL patients with DS)
      • ≥ 365 days and ≤ 31 years of age (B-LLy patients with or without DS)
    • COG AALL1732:A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#:772518) for Newly Diagnosed High‐Risk B‐ALL; Risk Adapted Post‐Induction Therapy for High‐Risk B‐ALL, Mixed Phenotype Acute Leukemia, and Disseminated B‐LLy
      • *AGE: > 365 days and < 25 years of age at diagnosis

    Mantle Cell Lymphoma

    Upfront:

    • ECOG EA4181: A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma
    • ECOG-ACRIN EA4151: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab alone for patients with Mantle Cell Lymphoma in minimal residual disease- negative first complete remission
    • PrECOG PrE0405: Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

    Relapsed/Refractory:

    • PrECOG PrE0404: Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
    • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    Melanoma

    ADJUVANT

    • No Trials Available

    ADVANCED

    First Line

    • ECOG EA6141: Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
    • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    Second Line

    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
    • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    Multiple Myeloma

    SMOLDERING MYELOMA

    • ECOG-ACRIN EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering (DETER-SMM)
    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

    MYELOMA

    First Line

    • ECOG EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation (NCT04566328)

    Relapsed

    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

    Maintenance

    • SWOG S1803: Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

    Myelodysplastic Syndrome

    • NHLBI-MDS: The National Myelodyplastic Syndromes (MDS) Study
    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

    Neuroblastoma

    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
    • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    Pediatric and Young Adult Oncology

    BRAIN

    • COG ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
      • *AGE: ≥ 3 years and < 22 years of age at the time of enrollment
    • COG ACNS1721: A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600 Mutations
      • *AGE: Stratum 2 (IDH mutant): ≥ 3 years of age and ≤ 25 years of age at the time of enrollment.
    • COG APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
      • *AGE: ≥ 12 months and ≤ 21 years of age at the time of study enrollment

    LEUKEMIA

    ALL

    • COG AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
      • *AGE: ≥ 365 days and < 10 years of age (B-ALL patients without DS)
      • ≥ 365 days and ≤ 31 years of age (B-ALL patients with DS)
      • ≥ 365 days and ≤ 31 years of age (B-LLy patients with or without DS)
    • COG AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#:772518) for Newly Diagnosed High‐Risk B‐ALL; Risk Adapted Post‐Induction Therapy for High‐Risk B‐ALL, Mixed Phenotype Acute Leukemia, and Disseminated B‐LLy
      • *AGE: > 365 days and < 25 years of age at diagnosis

    • COG AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
      • *AGE: > 1 year and < 21 years at ALL diagnosis
    • COG APEC14B1: Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
      • *AGE: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for which there is a higher upper age limit.

    AML

    • COG AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
      • *AGE: > 90 days and < 4 years of age at diagnosis of AML or Myelodysplastic Syndrome (MDS)
    • COG APEC14B1: Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
      • *AGE: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for which there is a higher upper age limit

    MPAL

    • COG AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#:772518) for Newly Diagnosed High‐Risk B‐ALL; Risk Adapted Post‐Induction Therapy for High‐Risk B‐ALL, Mixed Phenotype Acute Leukemia, and Disseminated B‐LLy
      • *AGE: > 365 days and < 25 years of age at diagnosis

    LYMPHOMA

    • SWOG S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.
      • *AGE: ≥ 12 years of age
    • ECOG-ACRIN E4412: A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
      • AGE: ≥ 12 years of age and <18 years of age
    • COG AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
      • *AGE: ≥ 365 days and < 10 years of age (B-ALL patients without DS)
      • ≥ 365 days and ≤ 31 years of age (B-ALL patients with DS)
      • ≥ 365 days and ≤ 31 years of age (B-LLy patients with or without DS)
    • COG AALL1732:A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#:772518) for Newly Diagnosed High‐Risk B‐ALL; Risk Adapted Post‐Induction Therapy for High‐Risk B‐ALL, Mixed Phenotype Acute Leukemia, and Disseminated B‐LLy
      • *AGE: > 365 days and < 25 years of age at diagnosis

    • COG APEC14B1: Project: EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
      • *AGE: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for which there is a higher upper age limit.
    • COG APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
      • *AGE: ≥ 12 months and ≤ 21 years of age at the time of study enrollment

    NEUROBLASTOMA

    • COG ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
      • *AGE: < 12 months (< 365 days) of age at diagnosis with INRG Stage L1; or < 18 months (< 547 days) of age at diagnosis with INRG Stage L2 or Stage Ms neuroblastoma/ganglioneuroblastoma.
    • COG ANBL00B1: Neuroblastoma Classification Biology Studies
    • COG APEC14B1: Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
      • *AGE: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for which there is a higher upper age limit.
    • COG APEC1621F: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment

    • COG APEC1621G: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621H: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621I: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621J: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
      • *AGE: ≥ 12 months and ≤ 21 years of age at the time of study enrollment

    SARCOMAS

    • COG ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
      • *AGE: ≤ 40 years of age at the time of enrollment
    • COG APEC14B1: Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
      • *AGE: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for which there is a higher upper age limit.
    • COG APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusions
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621D: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LY3023414 in Solid Tumors
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621E: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)– Phase 2 subprotocol of Selumetinib in patients with Tumors harboring activating MAPK pathway mutations
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621F: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment

    • COG APEC1621G: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations.
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621H: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621I: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621J: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
      • *AGE: ≥ 12 months and ≤ 21 years of age at the time of study enrollment

    OTHER (KIDNEY, LIVER, RETINO, GCT, RARE)

    • COG AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
      • *AGE: ≤ 30 years of age at the time of diagnosis
    • COG AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
      • *AGE: Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites)) Patients must be < 50 years of age at enrollment
      • Standard Risk 1 Patients must be < 11 years of age at enrollment
      • Standard Risk 2 Patients must be ≥ 11 and < 25 years of age at enrollment.
    • COG APEC14B1: Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
      • *AGE: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for which there is a higher upper age limit.
    • COG APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusions
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621D: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LY3023414 in Solid Tumors
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621E: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)– Phase 2 subprotocol of Selumetinib in patients with Tumors harboring activating MAPK pathway mutations
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621F: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment

    • COG APEC1621G: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621H: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621I: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621J: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
      • *AGE: ≥ than 12 months and ≤ 21 years of age at the time of study enrollment
    • COG APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
      • *AGE: ≥ 12 months and ≤ 21 years of age at the time of study enrollment

    LATE EFFECTS

    • COG ALTE03N1: Key Adverse Events after Childhood Cancer
      • *AGE: Diagnosis of primary cancer at age 21 or younger, irrespective of current age
    • COG ALTE07C1: Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer
      • *AGE: All ages

    Precision Medicine

    • SWOG S1609: "DART": Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
    • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    Prevention/Symptom Management

    • Wake Forest WF-30917CD: A Stepped-Care Telehealth Approach To Treat Distress In Rural Cancer Survivors
    • ECOG EAQ171CD: Implementing a Virtual Tobacco Treatment in Community Oncology Practices: "Smoke Free Support Study 2.0"

    Sarcoma

    • COG ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
      • *AGE: ≤ 40 years of age at the time of enrollment
    • Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
    • SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
    • ECOG EAY131 MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas

    Screenings

    • EA1151 TMIST: Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

    If you are interested in getting additional information on a research study, please contact:

    Lori Meyer, RN, OCN, CCRC
    (608) 775-2579 or (800) 362-9567, ext. 52579
    lameyer@gundersenhealth.org

    Christine Roraff, RN
    (608) 775-7001 or (800) 362-9567, ext. 57001
    cmroraff@gundersenhealth.org

    Jonean Thorsen, RN
    (608) 775-7001 or (800) 362-9567, ext. 57001
    jethorse@gundersenhealth.org

    what to expect

    We've taken steps at all our locations to keep you and our staff healthy and safe. Here's what to expect when you visit us.

    Stay safe